Our platform

Preclinical molecular imaging is a non-invasive technique that employs radioactive tracers to visualize, characterize and quantify biological processes in real-time at the molecular and cellular level in living animals.

With advanced preclinical imaging technologies and extensive expertise, OITL excels in conducting in vivo imaging studies across various research fields, including oncology, cardiovascular disease, neurology, inflammation, and fibrosis.

Our preclinical imaging platform is well-suited for high-throughput screening (HTS) of novel drug compounds, enabling researchers to accelerate the identification and development of promising drug candidates with precise, quantitative imaging data.

In vivo imaging in HTS also allows for non-invasive, longitudinal studies and more efficient collection of comprehensive data from fewer animals, supporting both scientific efficiency and ethical animal welfare standards.

Our platform is equipped to:

• Non-invasive molecular imaging in live animal models with both diagnostic and therapeutic radionuclides e.g. fluorine-18, gallium-68, zirconium-89, technecium-99m, lead-203, lead-212, actinium-225, radium-223, lutetium-177
• Perform in vivo biodistribution studies to assess the distribution across various tissues and organs of novel compounds in both healthy and diseased animals
• Assess target binding specificity and real-time drug-target interactions of drug candidates and how they interact with their intended molecular target(s) in vivo
• Conduct pharmacokinetics studies
• Monitor disease progression and response to radiotherapy or pharmacological intervention
• Use automated image analysis tools for the fast and efficient processing of imaging data, optimizing the throughput of screening processes